Molecular pathogenetics of renal cancer

American Journal of Nephrology

Volumn 26, Issue 3, 2006, Pages 218-231

  Skolarikos, Andreas A ^a   Papatsoris, Athanasios G ^a   Alivizatos, Gerasimos ^a   Deliveliotis, Charalambos ^a  

^a SISMANOGLIO HOSPITAL   (Greece)

Author keywords

Genetics; Molecular biology; Renal cancer

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BORTEZOMIB; CARBONATE DEHYDRATASE IX; CETUXIMAB; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GELDANAMYCIN; IPILIMUMAB; LENALIDOMIDE; PANITUMUMAB; RAPAMYCIN; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB; VON HIPPEL LINDAU PROTEIN; WX 250;

ALLELE; BIOCHEMISTRY; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 15; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 18; CHROMOSOME 2; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CYTOGENETICS; GENE DELETION; GENE MUTATION; GENE SILENCING; GENETIC LINKAGE; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CANCER; KIDNEY COLLECTING TUBULE; ONCOGENE; PAPILLARY CARCINOMA; PATHOGENESIS; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; X CHROMOSOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 33746394649     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093631     Document Type: Review

References (153)

1. Linehan WM, Grubb RL, Coleman JA, et al: The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management BJU Int 2005;95(suppl 2):2-7.
2. Pavlovich CP, Schmidt LS: Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004;4:381-393.
3. Hansel DE: Genetic alterations and histopathologic findings in familial renal cell carcinoma. Histol Histopathol 2006;21:437-444.
4. Kovacs G, Kung HF: Nonhomologous chromatid exchange in hereditary and sporadic renal cell carcinomas. Proc Natl Acad Sci USA 1991;88:194-198.
5. Van den Berg A, Buys CHCM: Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer 1997;19:59-76.
6. Alimov A, Kost-Alimova M, Liu J, et al: Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 2000;19:1392-1399.
7. Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
8. Kovacs G, Emanuel A, Neumann HP, et al: Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer 1991;3:256-262.
9. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
10. Teh BT, Giraud S, Sari NF, et al: Familial non-VHL non-papillary clear-cell renal cancer. Lancet 1997;349:848-849.
11. Woodward ER, Clifford SC, Astuti D, et al: Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 2000;37:348-353.
12. Martinez A, Fullwood P, Kishida T, et al: Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol 2000;53:137-144.
13. Lott ST, Lovell M, Naylor SL, et al: Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3q12. Cancer Res 1998;58:3533-3537.
14. Jülicher K, Marquitan G, Werner N, et al: Novel tumor suppressor locus in human chromosome region 3p14.2. J Natl Cancer Inst 1999;91:1563-1568.
15. Lovell M, Lott ST, Wong P, et al: The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. Cancer Res 1999;59:2182-2189.
16. Wang L, Darling J, Zhang JS, et al: Loss of expression of the DDR1 gene at chromosome segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 2000;27:1-10.
17. Dreijerink K, Braga E, Kuzmin I, et al: Candidate TSG, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001;98:7504-7509.
18. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699.
19. Engel JD, Kundu SD, Yang T, et al: Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (renca) cells. Urology 1999;54:164-170.
20. Ramp U, Jaquet K, Reinecke P, et al: Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 1997;76:739-739.
21. Kundu SD, Kim IY, Zelner D, et al: Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca. J Urol 1998;160:1883-1888.
22. Cardillo MR, Lazzereschi D, Gandini O, et al: Transforming growth factor-beta pathway in human renal cell carcinoma and surrounding normal-appearing renal parenchyma. Anal Quant Cytol Histol 2001;23:109-117.
23. Junker U, Haufe CC, Nuske K, et al: Elevated plasma TGF-beta1 in renal disease: cause or consequence? Cytokine 2000;12:1084-1091.
24. Audebert M, Chevillard S, Levalois C, et al: Alterations of the DNA repair gene OGG1 in human clear cell carcinomas of the kidney. Cancer Res 2000;60:4740-4744.
25. Bodmer D, van den Hurk W, van Groningen JJM, et al: Understanding familial and non-familial renal cell cancer. Hum Mol Genet 2002;11:2489-2498.
26. Bugert P, Pesti T, Kovacs G: The tcf17 gene at chromosome 5q is not involved in the development of conventional renal cell carcinoma. Int J Cancer 2000;86:806-810.
27. Yang ZQ, Yoshida MA, Fukuda Y, et al: Molecular cytogenetic analysis of 17 renal cancer cell lines: increased copy number at 5q31-33 in cell lines from nonpapillary carcinomas. Jpn J Cancer Res 2000;91:156-163.
28. Gurova KV, Hill JE, Razorenova OV, et al: p53 Pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:1951-1958.
29. Walther MM, Enquist EG, Jennings SB, et al: Molecular genetics of renal cell carcinoma; in Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds): Comprehensive Textbook of Genitourinary Oncology, ed 2. Philadelphia, Lippincott, Williams & Wilkins, 2000, pp 116-128.
30. Rochlitz CF, Peter S, Wiliroth G, et al: Mutations in the ras protooncogenes are rare events in renal cell cancer. Eur J Cancer 1992;28:333-336.
31. Latif Z, Waters AD, Bartlett JMS, et al: Gene amplification and over expression of HER2 in renal cell carcinoma. BJU Int 2002;89:5-9.
32. Kinouchi T, Saiki S, Naoe T, et al: Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma. Cancer Res 1989;49:3627-3630.
33. Slamon DJ, deKernion JB, Verma IM, et al: Expression of cellular oncogenes in human malignancies. Science 1984;224:256-262.
34. Argiles A, Kraft N, Ootaka T, et al: Epidermal growth factor and transforming growth factor alpha stimulate or inhibit proliferation of a human renal adenocarcinoma cell line depending on cell status: differentiation of the two pathways by G protein involvement. Cancer Res 1992;52:4356-4560.
35. Petrides PE, Bock S, Bovens J, Hofmann R, Jakse G: Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res 1990;50:3934-3939.
36. Atlas I, Mendelsohn J, Baselga J, et al: Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 1992;52:3335-3339.
37. Gomella LG, Anglard P, Sargent ER, et al: Epidermal growth factor receptor gene analysis in renal cell carcinoma. J Urol 1990;143:191-193.
38. De Paulsen N, Brychzy A, Fournier MC, et al: Role of transforming growth factor-α in von Hippel-Lindau (VHL) (-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98:1387-1392.
39. Kochevar GJ, Stanek JA, Rucker EB: Truncated fibronectin. An autologous growth-promoting substance secreted by renal carcinoma cells. Cancer 1992;69:2311-2315.
40. Kobayashi T, Honke K, Gasa S, et al: Hepatocyte growth factor elevates the activity levels of glycolipid sulfotransferases in renal cell carcinoma cells. Eur J Biochem 1994;219:407-413.
41. Nishimura N, Kanda S, Yogi Y, et al: Secretion of autocrine growth-promoting activity by renal-carcinoma cells treated with 5-fluorouracil. Int J Cancer 1992;52:105-109.
42. Klotz LH, Kulkarni C, Mills G: End stage renal disease serum contains a specific renal cell growth factor. J Urol 1991;145:156-160.
43. Pavlovich CP, Schmidt LS, Phillips JL: The genetic basis of renal cell carcinoma. Urol Clin North Am 2003;30:437-454.
44. Delahunt B, Eble JN, McCredie MR, et al: Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001;32:590-595.
45. Lubensky IA, Schmidt L, Zhuang Z, et al: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999;155:517-526.
46. Jiang F, Richter J, Schraml P, et al: Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998;153:1467-1473.
47. Kovacs G, Fuzesi L, Emanual A, et al: Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer 1991;3:249-255.
48. Reutzel D, Mende M, Naumann S, et al: Genomic imbalances in 61 renal cancers from the proximal tubulus detected by comparative genomic hybridization. Cytogenet Cell Genet 2001;93:221-227.
49. Heimann P, El Housni H, Ogur G, et al: Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17) (p11.2;q25.3)-bearing papillary renal cell carcinomas. Cancer Res 2001;61:4130-4135.
50. Weterman MAJ, Wilbrink M, Geurts van Kessel A: Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)- positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 1996;93:15294-15298.
51. Beckmann H, Su LK, Kadesh T: TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer μE3 motif. Genes Dev 1990;4:167-179.
52. Weterman MAJ, van Groningen JM, Jansen A, et al: Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene 2000;19:69-74.
53. Weterman MAJ, van Groningen JM, den Hartog A, et al: Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes. Oncogene 2001;20:1414-1424.
54. Wassmann K, Benezra R: Mitotic checkpoints: from yeast to cancer. Curr Opin Genet Dev 2001;11:83-90.
55. Chen J, Fang G: MAD2B is an inhibitor of the anaphase-promoting complex. Genes Dev 2001;15:1765-1770.
56. Peters JM: The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 2002;9:931-943.
57. Pfleger CM, Salic A, Lee E, et al: Inhibition of Cdh1-APC by MAD2L2: a novel mechanism of regulating Cdhl. Genes Dev 2001;15:1759-1764.
58. Clark J, Lu YJ, Sidhar S, Parker C, et al: Fusion of the splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997;15:2233-2239.
59. Skalsky YM, Ajuh PM, Parker C, et al: PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors. Oncogene 2001;20:178-187.
60. Schmidt L, Junker K, Nakaigawa N, et al: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-2350.
61. Glukhova L, Lavialle C, Fauvet D, et al: Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene. Oncogene 2000;19:754-761.
62. Nagashima Y, Inayama Y, Kato Y, et al: Pathological and molecular biological aspects of the renal epithelial neoplasms, up-to-date. Pathol Int 2004;54:377-386.
63. Schwerdtle RF, Storkel S, Neuhaus C, et al: Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res 1996, 56:2927-2930.
64. Velickovic M, Delahunt B, Storkel S, et al: VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res 2001;61:4815-4819.
65. Contractor H, Zariwala M, Bugert P, et al: Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 1997;181:136-139.
66. Nickerson M, Warren M, Toro J, et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2002;2:157-164.
67. Fuzesi L, Cober M, Mittermayer C: Collecting duct carcinoma: cytogenetic characterization. Histopathology 1992;21:155-160.
68. Verdorfer I, Culig Z, Hobisch A, et al: Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation. Int J Oncol 1998;13:461-464.
69. Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg RE, Kolenko V: The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am 2003;30:423-426.
70. Latif F, Tory K, Gnarra JR, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
71. Knudson AG Jr: Genetics of human cancer. Annu Rev Genet 1986;20:231-251.
72. Stolle C, Glenn G, Zbar B, et al: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-423.
73. Prowse AH, Webster AR, Richards FM, et al: Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997;60:765-771.
74. Uzzo RG, Novick AC: von Hippel-Lindau syndrome: clinical and molecular considerations for the urologist. AUA Update Ser 1999;18:137-144.
75. Choyke PL, Glenn GM, Walther MM, et al: von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995;194:629-642.
76. Chen F, Kishida T, Yao M, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
77. Crossey PA, Richards FM, Foster K, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-1308.
78. Schoenfeld A, Davidowitz E, Burk R: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1 1998;95:8817-8822.
79. Blankenship C, Naglich J, Whaley J, et al: Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 1999;18:1529-1535.
80. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10(suppl):6290-6295.
81. Kim W, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003;13:55-60.
82. George DJ, Kaelin WG Jr: The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349:419-421.
83. Epstein A, Gleadle J, McNeill L, et al: Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
84. Berra E, Benizri E, Ginouves A, et al: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003;22:4082-4090.
85. Ivan M, Haberberger T, Gervasi DC, et al: Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002;99:13459-13464.
86. Bruick R, McKnight S: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-1340.
87. 2 sensing. Science 2001;292:464-468.
88. Yu F, White S, Zhao Q, et al: HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001;98:9630-9635.
89. Jaakkola P, Mole D, Tian Y, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472.
90. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
91. Lidgren A, Hedberg Y, Grankvist K, et al: The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;1:1129-1135.
92. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-427.
93. Pantuck AJ, Zeng G, Belldegrum AS, et al: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma. Exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641-4652.
94. Okuda H, Saitoh K, Hirai S, et al: The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C J Biol Chem 2001;276:43611-43617.
95. Cohen H, Zhou M, Welsh A, et al: An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 1999;266:43-50.
96. Pioli PA, Rigby WF: The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J Biol Chem 2001;276:40346-40352.
97. Kuznetsova AV, Meller J, Schnell PO, et al: von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination. Proc Natl Acad Sci USA 2003;100:2706-2711.
98. Na X, Duan HO, Messing EM, et al: Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J 2003;22:4249-4259.
99. Zhou MI, Wang H, Ross JJ, et al: The von Hippel-Lindau (VHL) tumor suppressor stabilizes novel PHD protein Jade-1. J Biol Chem 2002;277:39887- 39898.
100. Li Z, Na X, Wang D, et al: Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem 2002;277:4656-4662.
101. Ohh M, Yauch RL, Lonergan KM, et al: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968.
102. Hergovich A, Lisztwan J, Barry R, et al: Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70.
103. An J, Rettig MB: Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005;25:7546-7556.
104. Atkins DJ, Gingert C, Justnhoven C, et al: Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas. Virchows Arch 2005;447:634-642.
105. Petrella BL, Lohi J, Brinckerhoff CE: Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005;3:1043-1052.
106. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, et al: von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res 2006;66:1553-1560.
107. Maina EN, Morris MR, Zatyka M, et al: Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene 2005;30:4549-4558.
108. Ornstein DK, Lubensky IA, Venzon D, et al: Prevalence of microscopic tumors in normal appearing renal parenchyma from patients with hereditary papillary renal cancer. J Urol 2000;163:431-433.
109. Schmidt L, Duh F-M, Chen F, et al: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
110. Dean M, Park M, Le Beau MM, et al: The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985;318:385-388.
111. Fischer J, Palmedo G, von Knobloch R, et al: Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998;17:733-739.
112. Zhuang Z, Park WS, Pack S, et al: Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998;20:66-69.
113. Jeffers M, Fiscella M, Webb CP, et al: The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998;95:14417-14422.
114. Zbar B, Glenn G, Lubensky I, et al: Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995;153:907-912.
115. Tomlinson IP, Alam NA, Rowan AJ, et al: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-410.
116. Toro JR, Nickerson ML, Wei MH, et al: Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106.
117. Alam NA, Olpin S, Rowan A, et al: Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn 2005;7:437-443.
118. Pollard P, Wortham N, Barclay E, et al: Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005;205:41-49.
119. Pavlovich CP, Grubb RL 3rd, Hurley K, et al: Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005 173:1482-1486.
120. Schmidt LS, Nickerson ML, Warren MB, et al: Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet 2005;76:1023-1033.
121. Khoo SK, Kahnoski K, Sugimura J et al: Inactivation of BHD in sporadic renal tumors. Cancer Res 2003;63:4583-4587.
122. Okimoto K, Sakurai J, Kobayashi T, et al: A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc Natl Acad Sci USA 2004 101:2023-2027.
123. Lingaas F, Comstock KE, Kirkness EF, et al: A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German shepherd dog. Hum Mol Genet 2003;12:3043-3053.
124. Pavlovich CP, Walther MM, Eyler RA, et al: Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 2002;26:1542-1552.
125. Warren MB, Torres-Cabala CA, Turner ML, et al: Expression of Birt-Hogg-Dubé mRNA in normal and neoplastic human tissues. Mod Pathol 2004;17:998-1011.
126. Rodriíguez-Perales S, Meléndez B, Gribble SM, et al: Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. Hum Mol Genet 2004;13:983-990.
127. Cohen, AJ, Li FP, Berg S, et al: Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592-595.
128. Kovacs G, Brusa P, De Riese W: Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989;43:422-427.
129. Koolen MI, van der Meyden AP, Bodmer D: A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. Kidney Int 1998;53:273-275.
130. van Kessel A, Wijnhoven H, Bodmer D, et al: Renal cell cancer: chromosome 3 translocations as risk factors. J Natl Cancer Inst 1999;91:1159-1160.
131. Podolski J, Byrski T, Zajaczek S, et al: Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J Hum Genet 2001;46:685-693.
132. Eleveld MJ, Bodmer D, Merkx G, et al: Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). Genes Chromosomes Cancer 2001;31:23-32.
133. Kanayama H, Lui WO, Takahashi M, et al: Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma. J Med Genet 2001;38:165-170.
134. Schmidt L, Li F, Brown RS, et al: Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1995;1:191.
135. Bodmer D, Eleveld MJ, Ligtenberg MJ, et al: An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet 1998;62:1475-1483.
136. Simpson L, He X, Pins M, et al: Renal medullary carcinoma and ABL gene amplification. J Urol 2005 173:1883-1888.
137. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918.
138. Davis NB, Taber DA, Ansari RH, et al: Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004;22:115-119.
139. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(suppl):55-61.
140. Kim MS, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-443.
141. Rapisarda A, Uranchimeg B, Sordet O, et al: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-1482.
142. Welsh S, Williams R, Kirkpatrick L, et al: Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3:233-244.
143. Mabjeesh NJ, Escuin D, LaVallee TM, et al: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.
144. Ratain MJ, Flaherty KT, Stadler WM, et al: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Proc Am Soc Clin Oncol 2004;23:381.
145. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
146. Motzer RJ, Amato R, Todd M, et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99-101.
147. Drucker BJ, Schwartz L, Marion S, et al: Phase II trial of ZD (Iressa), an EGF inhibitor, in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2002;21:181.
148. Ciardiello F, Caputo R, Damiano V, et al: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-1556.
149. Motzer RJ, Michaelson MD, Redman BG et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;1; 24:16-24.
150. Bartlett JB, Michael A, Clarke IA, et al: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955-961.
151. Bleumer I, Knuth A, Oosterwijk E, et al: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90:985-990.
152. Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;15:3601-3603.
153. Linehan WM, Vasselli J, Srinivasan R, et al: Genetic basis of cancer of the kidney disease-specific approaches to therapy. Clin Cancer Res 2004;10(suppl):6282-6289.